<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(1)</volume><submitter>Nair-Shalliker V</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The aim is to determine the effects of obesity and metformin-use in predicting prostate cancer (PC) risk.&lt;h4>Methods&lt;/h4>We used male participants from the Sax Institute's 45 and Up Study (Australia), recruited between 2005-2009. Participants completed a questionnaire at recruitment which included information on self-reported body mass index (BMI; kg/m&lt;sup>2&lt;/sup>). Participants' baseline data were linked by the Centre for Health Record Linkage to the NSW Cancer Registry and to Services Australia to identify index prescription claims for diabetic medications between January 2012 and December 2019. Multivariable Joint Cox regression analyses were used to examine associations between BMI, diabetic medications, and PC risk by cancer spread.&lt;h4>Results&lt;/h4>Of the 94,674 elig</pubmed_abstract><journal>BJC reports</journal><pagination>2</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12867996</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men.</pubmed_title><pmcid>PMC12867996</pmcid><pubmed_authors>Smith DP</pubmed_authors><pubmed_authors>Radhika-Chand R</pubmed_authors><pubmed_authors>Bang A</pubmed_authors><pubmed_authors>Chiam K</pubmed_authors><pubmed_authors>Nair-Shalliker V</pubmed_authors><pubmed_authors>Joshua AM</pubmed_authors><pubmed_authors>Greenfield JR</pubmed_authors><pubmed_authors>David M</pubmed_authors><pubmed_authors>Patel MI</pubmed_authors></additional><is_claimable>false</is_claimable><name>Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men.</name><description>&lt;h4>Background&lt;/h4>The aim is to determine the effects of obesity and metformin-use in predicting prostate cancer (PC) risk.&lt;h4>Methods&lt;/h4>We used male participants from the Sax Institute's 45 and Up Study (Australia), recruited between 2005-2009. Participants completed a questionnaire at recruitment which included information on self-reported body mass index (BMI; kg/m&lt;sup>2&lt;/sup>). Participants' baseline data were linked by the Centre for Health Record Linkage to the NSW Cancer Registry and to Services Australia to identify index prescription claims for diabetic medications between January 2012 and December 2019. Multivariable Joint Cox regression analyses were used to examine associations between BMI, diabetic medications, and PC risk by cancer spread.&lt;h4>Results&lt;/h4>Of the 94,674 elig</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-15T11:22:34.643Z</modification><creation>2026-07-04T03:12:17.13Z</creation></dates><accession>S-EPMC12867996</accession><cross_references><pubmed>41634377</pubmed><doi>10.1038/s44276-025-00201-x</doi></cross_references></HashMap>